Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Feb 05 2019 Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference Jan 07 2019 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 Dec 27 2018 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Nov 12 2018 Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results Nov 06 2018 Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results Oct 23 2018 Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference Oct 04 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies Sep 26 2018 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference Sep 12 2018 Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors Sep 10 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer Aug 29 2018 Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference Aug 09 2018 Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results Aug 01 2018 Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results May 14 2018 Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results May 08 2018 Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results Apr 17 2018 Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia Apr 16 2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting Mar 28 2018 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Mar 21 2018 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results Mar 15 2018 Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting Mar 06 2018 Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference Feb 21 2018 Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations Feb 06 2018 Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference Jan 24 2018 Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference Jan 09 2018 Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 Pagination First page « first Previous page ‹ previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Feb 05 2019 Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference Jan 07 2019 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019 Dec 27 2018 Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Nov 12 2018 Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results Nov 06 2018 Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results Oct 23 2018 Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference Oct 04 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies Sep 26 2018 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference Sep 12 2018 Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors Sep 10 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer Aug 29 2018 Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference Aug 09 2018 Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results Aug 01 2018 Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results May 14 2018 Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results May 08 2018 Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results Apr 17 2018 Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia Apr 16 2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting Mar 28 2018 Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results Mar 21 2018 Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results Mar 15 2018 Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting Mar 06 2018 Cyclacel Pharmaceuticals to Present at the 30th Annual ROTH Conference Feb 21 2018 Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations Feb 06 2018 Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference Jan 24 2018 Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference Jan 09 2018 Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for 2018 Pagination First page « first Previous page ‹ previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page next › Last page last »
Jan 07 2019 Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019
Oct 04 2018 Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies
Sep 10 2018 Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer
Aug 29 2018 Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference
Apr 17 2018 Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia
Apr 16 2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting
Mar 15 2018 Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting
Feb 21 2018 Cyclacel Announces Notice of Grant of New European Patent Covering Sapacitabine Pharmaceutical Formulations
